BR112017027448A2 - vacina contra rsv - Google Patents
vacina contra rsvInfo
- Publication number
- BR112017027448A2 BR112017027448A2 BR112017027448A BR112017027448A BR112017027448A2 BR 112017027448 A2 BR112017027448 A2 BR 112017027448A2 BR 112017027448 A BR112017027448 A BR 112017027448A BR 112017027448 A BR112017027448 A BR 112017027448A BR 112017027448 A2 BR112017027448 A2 BR 112017027448A2
- Authority
- BR
- Brazil
- Prior art keywords
- mutation
- rsv
- amino acid
- polypeptide
- fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a composições compreendendo um polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) recombinante que é estabilizado na conformação pré-fusão, em que o referido polipeptídeo (rsv) (f) compreende pelo menos uma mutação em comparação com um polipeptídeo (rsv) (f) de tipo selvagem, em que a pelo menos uma mutação é selecionada do grupo consistindo de: a) uma mutação do aminoácido ácido aspártico (d) na posição 486, b) uma mutação do aminoácido ácido aspártico (d) na posição 489 e c) uma mutação do aminoácido serina (s) na posição 398 e/ou do aminoácido lisina (k) na posição 394. a invenção também refere-se a composições compreendendo uma molécula de ácido nucleico isolado codificando os referidos polipeptídeos (rsv) (f) estáveis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15175647 | 2015-07-07 | ||
PCT/EP2016/066098 WO2017005844A1 (en) | 2015-07-07 | 2016-07-07 | Vaccine against rsv |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017027448A2 true BR112017027448A2 (pt) | 2018-09-04 |
Family
ID=53539547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017027448A BR112017027448A2 (pt) | 2015-07-07 | 2016-07-07 | vacina contra rsv |
Country Status (16)
Country | Link |
---|---|
US (3) | US10456462B2 (pt) |
EP (2) | EP3319633B1 (pt) |
JP (1) | JP7189014B2 (pt) |
KR (1) | KR102638978B1 (pt) |
CN (2) | CN116059336A (pt) |
AU (2) | AU2016289492B2 (pt) |
BR (1) | BR112017027448A2 (pt) |
CA (1) | CA2991002C (pt) |
DK (1) | DK3319633T3 (pt) |
EA (1) | EA039065B1 (pt) |
ES (1) | ES2839880T3 (pt) |
HK (1) | HK1250939A1 (pt) |
IL (2) | IL288541B (pt) |
PL (1) | PL3319633T3 (pt) |
WO (1) | WO2017005844A1 (pt) |
ZA (1) | ZA201800092B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
CN116059336A (zh) | 2015-07-07 | 2023-05-05 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
CA3025441A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
MX2019011869A (es) | 2017-04-04 | 2020-01-09 | Univ Washington | Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. |
EP3624844A1 (en) * | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
KR20200138234A (ko) | 2018-02-28 | 2020-12-09 | 유니버시티 오브 워싱톤 | 자기 조립 나노구조 백신 |
KR20210091749A (ko) * | 2018-11-13 | 2021-07-22 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합전 rsv f 단백질 |
BR112022013720A2 (pt) | 2020-01-16 | 2022-10-11 | Janssen Pharmaceuticals Inc | Mutante fimh, composições com o mesmo e seu uso |
KR20220164543A (ko) | 2020-04-02 | 2022-12-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 백신 조성물 |
CA3207841A1 (en) | 2021-01-12 | 2022-07-21 | Janssen Pharmaceuticals, Inc | Fimh mutants, compositions therewith and use thereof |
CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
CN116003536A (zh) * | 2022-09-23 | 2023-04-25 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
CN117986382A (zh) * | 2022-11-04 | 2024-05-07 | 北京康乐卫士生物技术股份有限公司 | 针对rsv的重组亚单位疫苗及其应用 |
US20240252612A1 (en) | 2022-12-11 | 2024-08-01 | Pfizer Inc. | Immunogenic compositions and uses thereof |
US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US17543A (en) * | 1857-06-09 | Improvement in power printing-presses | ||
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5994108A (en) | 1991-11-05 | 1999-11-30 | Board Of Regents, The University Of Texas System | Mutant TAR virus and transdominant tat mutants as pharmacological agents |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
US6485958B2 (en) | 1996-07-01 | 2002-11-26 | Gencell Sa | Method for producing recombinant adenovirus |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US5851808A (en) | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
WO1998039411A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
ES2272053T3 (es) | 1998-02-17 | 2007-04-16 | Schering Corporation | Composiciones que comprenden virus y metodos para concentrar preparaciones de virus. |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
ES2323991T3 (es) | 1998-11-16 | 2009-07-28 | Introgen Therapeutics, Inc. | Formulacion de adenovirus para terapia genica. |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
ATE485382T1 (de) | 1999-05-17 | 2010-11-15 | Crucell Holland Bv | Rekombinantes adenovirus des ad26-serotyps |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6281823B1 (en) | 1999-09-21 | 2001-08-28 | Agere Systems Guardian Corp. | Direct digital synthesis using a sine weighted DAC |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
JP5118798B2 (ja) | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
CA2415688A1 (en) | 2000-05-08 | 2001-11-15 | Anand Rao | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
AUPR878401A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
JP2005517394A (ja) | 2001-12-12 | 2005-06-16 | エフ エイチ フォールディング アンド カンパニー リミテッド | ウイルス保存のための組成物 |
RU2004125283A (ru) | 2002-01-18 | 2005-06-10 | Шеринг Акциенгезельшафт (De) | Стабилизированные композиции аденовируса |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
NZ534865A (en) | 2002-04-25 | 2008-07-31 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
MXPA04008891A (es) | 2002-04-25 | 2004-11-26 | Crucell Holland Bv | Medios y metodos para la produccion de vectores de adenovirus. |
EP1783212B1 (en) | 2002-05-14 | 2011-01-05 | Merck Sharp & Dohme Corp. | Methods of adenovirus purification |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
WO2004020971A2 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
DE602006003420D1 (de) | 2005-04-11 | 2008-12-11 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
US8772256B2 (en) | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
EP4219566A3 (en) | 2007-12-24 | 2023-09-06 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
EP2257809B1 (en) | 2008-02-29 | 2012-02-08 | Tibotec Pharmaceuticals | Method for identifying inhibitors against viruses that use a class i fusion protein |
US8225289B2 (en) | 2008-03-04 | 2012-07-17 | Wind River Systems, Inc. | Method and system for improved tool interaction with a target |
WO2010060719A1 (en) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
WO2010077717A1 (en) | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
CN101464897A (zh) | 2009-01-12 | 2009-06-24 | 阿里巴巴集团控股有限公司 | 一种词匹配及信息查询方法及装置 |
MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
EA201270062A1 (ru) | 2009-06-24 | 2013-02-28 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК | Вакцина |
US9492531B2 (en) | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
ES2918381T3 (es) | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | Composiciones de proteína F de VRS y métodos para producir las mismas |
KR101778317B1 (ko) | 2009-08-13 | 2017-09-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법 |
KR101749779B1 (ko) | 2009-10-15 | 2017-06-21 | 크루셀 홀란드 비.브이. | 아데노바이러스 입자의 정제 방법 |
DK2488635T3 (en) | 2009-10-15 | 2014-02-24 | Crucell Holland Bv | A method for purifying adenovirus of cultures with high cell density |
US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
EP2534135A2 (en) | 2010-02-12 | 2012-12-19 | KRKA, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
WO2012003466A1 (en) | 2010-07-02 | 2012-01-05 | Ensysce Biosciences, Inc. | Single-walled carbon nanotube/sirna complexes and methods related thereto |
BR112012031638B1 (pt) | 2010-07-09 | 2021-01-12 | Janssen Vaccines & Prevention B.V. | anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado |
US8317672B2 (en) | 2010-11-19 | 2012-11-27 | Kensey Nash Corporation | Centrifuge method and apparatus |
JP2014519819A (ja) | 2011-05-13 | 2014-08-21 | ノバルティス アーゲー | 融合前rsvf抗原 |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾピリダジン |
BR112014023196B1 (pt) | 2012-03-22 | 2021-09-08 | Janssen Vaccines & Prevention B.V. | Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
WO2014077096A1 (ja) | 2012-11-15 | 2014-05-22 | 一般財団法人化学及血清療法研究所 | ベクターワクチンおよび生ワクチンの併用による感染症の予防方法 |
CA2902877A1 (en) * | 2013-03-13 | 2014-10-02 | Jeffrey Boyington | Prefusion rsv f proteins and their use |
US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
CA2904758A1 (en) | 2013-03-14 | 2014-09-25 | Peroxyium, Inc., Delaware C Corp. | Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceo2 particles via nano-encapsulation and coating |
US10035842B2 (en) | 2013-04-15 | 2018-07-31 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G proteins |
EA035861B1 (ru) | 2013-04-15 | 2020-08-21 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела человека, связывающиеся с g-белком rsv |
DK2988780T3 (en) | 2013-04-25 | 2019-04-08 | Janssen Vaccines & Prevention Bv | STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES |
EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
ME03324B (me) | 2013-09-19 | 2019-10-20 | Janssen Vaccines & Prevention Bv | Poboljšanje adenovirusnih formulacija |
CA2951430A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
JP6350376B2 (ja) | 2015-04-23 | 2018-07-04 | 住友金属鉱山株式会社 | 非水系電解質二次電池用正極活物質及びその製造方法、並びにその正極活物質を用いた非水系電解質二次電池 |
CN116059336A (zh) | 2015-07-07 | 2023-05-05 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
BR112017028449A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | polipeptídeos rsv f pré-fusão solúveis estabilizados |
MA43763B1 (fr) | 2016-04-05 | 2021-03-31 | Janssen Vaccines & Prevention Bv | Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs |
EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
CA3025441A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US10522129B2 (en) | 2016-10-06 | 2019-12-31 | Gopro, Inc. | Active acoustic and vibration noise canceling in waterproof camera |
KR20180056310A (ko) | 2016-11-18 | 2018-05-28 | 삼성전자주식회사 | 복합양극활물질, 이를 채용한 양극과 리튬전지 및 그 제조방법 |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
BR112020004143A2 (pt) | 2017-09-15 | 2020-09-01 | Janssen Vaccines & Prevention B.V. | método para a indução segura de imunidade contra vírus sincicial respiratório (rsv) |
KR20210091749A (ko) | 2018-11-13 | 2021-07-22 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합전 rsv f 단백질 |
MX2021012991A (es) | 2019-04-25 | 2021-12-10 | Janssen Vaccines & Prevention Bv | Antigenos de gripe recombinantes. |
CN113924113A (zh) | 2019-05-15 | 2022-01-11 | 扬森疫苗与预防公司 | 季节性流感疫苗与基于腺病毒的呼吸道合胞病毒疫苗的共同施用 |
US20220193219A1 (en) | 2019-05-15 | 2022-06-23 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
KR20220164543A (ko) | 2020-04-02 | 2022-12-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 백신 조성물 |
CA3188170A1 (en) | 2020-06-29 | 2022-01-06 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
-
2016
- 2016-07-07 CN CN202211142491.4A patent/CN116059336A/zh active Pending
- 2016-07-07 EP EP16736161.7A patent/EP3319633B1/en active Active
- 2016-07-07 DK DK16736161.7T patent/DK3319633T3/da active
- 2016-07-07 BR BR112017027448A patent/BR112017027448A2/pt active Search and Examination
- 2016-07-07 EA EA201890220A patent/EA039065B1/ru unknown
- 2016-07-07 JP JP2018500567A patent/JP7189014B2/ja active Active
- 2016-07-07 AU AU2016289492A patent/AU2016289492B2/en active Active
- 2016-07-07 EP EP20199540.4A patent/EP3821906A1/en active Pending
- 2016-07-07 IL IL288541A patent/IL288541B/en unknown
- 2016-07-07 US US15/742,249 patent/US10456462B2/en active Active
- 2016-07-07 PL PL16736161T patent/PL3319633T3/pl unknown
- 2016-07-07 ES ES16736161T patent/ES2839880T3/es active Active
- 2016-07-07 WO PCT/EP2016/066098 patent/WO2017005844A1/en active Application Filing
- 2016-07-07 CA CA2991002A patent/CA2991002C/en active Active
- 2016-07-07 KR KR1020187003629A patent/KR102638978B1/ko active IP Right Grant
- 2016-07-07 CN CN201680039241.4A patent/CN107847580B/zh active Active
-
2017
- 2017-12-25 IL IL256561A patent/IL256561B/en unknown
-
2018
- 2018-01-05 ZA ZA2018/00092A patent/ZA201800092B/en unknown
- 2018-08-14 HK HK18110428.1A patent/HK1250939A1/zh unknown
-
2019
- 2019-10-01 US US16/589,601 patent/US11229694B2/en active Active
-
2022
- 2022-01-10 US US17/572,097 patent/US11998597B2/en active Active
- 2022-11-08 AU AU2022268296A patent/AU2022268296A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL256561A (en) | 2018-06-28 |
CA2991002A1 (en) | 2017-01-12 |
EP3821906A1 (en) | 2021-05-19 |
CN116059336A (zh) | 2023-05-05 |
AU2016289492A1 (en) | 2018-03-01 |
US20200061183A1 (en) | 2020-02-27 |
EA201890220A1 (ru) | 2018-06-29 |
IL288541B (en) | 2022-08-01 |
EP3319633B1 (en) | 2020-11-11 |
DK3319633T3 (da) | 2021-02-01 |
AU2022268296A1 (en) | 2022-12-15 |
US11998597B2 (en) | 2024-06-04 |
US10456462B2 (en) | 2019-10-29 |
ES2839880T3 (es) | 2021-07-06 |
IL288541A (en) | 2022-02-01 |
HK1250939A1 (zh) | 2019-01-18 |
KR20180027560A (ko) | 2018-03-14 |
CN107847580B (zh) | 2022-08-12 |
PL3319633T3 (pl) | 2021-04-19 |
US20220125912A1 (en) | 2022-04-28 |
WO2017005844A1 (en) | 2017-01-12 |
IL256561B (en) | 2022-01-01 |
EP3319633A1 (en) | 2018-05-16 |
US11229694B2 (en) | 2022-01-25 |
EA039065B1 (ru) | 2021-11-29 |
KR102638978B1 (ko) | 2024-02-22 |
JP2018520159A (ja) | 2018-07-26 |
AU2016289492B2 (en) | 2022-08-11 |
ZA201800092B (en) | 2021-07-28 |
CN107847580A (zh) | 2018-03-27 |
JP7189014B2 (ja) | 2022-12-13 |
US20180200360A1 (en) | 2018-07-19 |
CA2991002C (en) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017027448A2 (pt) | vacina contra rsv | |
BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
BR112017019625A2 (pt) | udp-glicosiltransferases | |
EA201892250A1 (ru) | Вакцина против rsv | |
BR112019004189A2 (pt) | trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos | |
BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
BR112018003665A2 (pt) | métodos e composições para vetores virais de evasão de anticorpo | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
BR112018076215A2 (pt) | partículas e composições de nicotina | |
BR112016013138A2 (pt) | mistura de peptídeos | |
WO2010036970A3 (en) | Influenza vaccines, antigens, compositions, and methods | |
PE20190110A1 (es) | Proteinas f de prefusion del vrs estabilizadas | |
BR112017020308A2 (pt) | udp-glicosiltransferases | |
BR112015029635A2 (pt) | polipeptídeo do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, e, composição | |
WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
BR112018077358A2 (pt) | tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma | |
BR112018073681A2 (pt) | análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico | |
BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
EA201892554A1 (ru) | Мутант cd200 и его применения | |
EA201792362A8 (ru) | Композиции и способы для лечения целиакии спру | |
BR112018010887A2 (pt) | polipeptídeo de fusão | |
BR112018001121A2 (pt) | vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |